Management of Newly Diagnosed Myeloma

S. Vincent Rajkumar, Antonio Palumbo

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


The treatment of multiple myeloma has changed dramatically in the last decade with the introduction of thalidomide, bortezomib, and lenalidomide. Patients eligible for autologous stem cell transplantation (ASCT) are treated with non-alkylating agent-containing regimens as initial therapy; typically thalidomide-dexamethasone or lenalidomide-dexamethasone. For patients not eligible for ASCT, the current standard of care is melphalan, prednisone, and thalidomide. Ongoing trials will soon assess if combinations including melphalan and prednisone plus bortezomib or MP plus lenalidomide may be considered an attractive option. Patients who have risk factors, such as deletion 13 or translocation t(4;14) or t(14;16), are candidates for novel, more aggressive treatments.

Original languageEnglish (US)
Pages (from-to)1141-1156
Number of pages16
JournalHematology/Oncology Clinics of North America
Issue number6
StatePublished - Dec 2007

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Management of Newly Diagnosed Myeloma'. Together they form a unique fingerprint.

Cite this